Source:http://linkedlifedata.com/resource/pubmed/id/17064986
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
2006-10-26
|
| pubmed:abstractText |
The aim of the study was to investigate the feasibility of mobilizing Philadelphia chromosome negative (Ph-) blood stem cells (BSC) with intensive chemotherapy and lenograstim (G-CSF) in patients with CML in first chronic phase (CP1). During 1994-1999 12 centers included 37 patients <56 years. All patients received 6 months' IFN, stopping at median 36 (1-290) days prior to the mobilization chemotherapy. All received one cycle of daunorubicin 50 mg/m2 and 1 hour infusion on days 1-3, and cytarabine (ara-C) 200 mg/m2 24 hours' i.v. infusion on days 1-7 (DA) followed by G-CSF 526 microg s.c. once daily from day 8 after the start of chemotherapy. Leukaphereses were initiated when the number of CD 34+ cells was >5/microl blood. Patients mobilizing poorly could receive a 4-day cycle of chemotherapy with mitoxantrone 12 mg/m2/day and 1 hour i.v infusion, etoposide 100 mg/m2/day and 1 hour i.v. infusion and ara-C 1 g/m2/twice a day with 2 hours' i.v infusion (MEA) or a second DA, followed by G-CSF 526 microg s.c once daily from day 8 after the start of chemotherapy. Twenty-seven patients received one cycle of chemotherapy and G-CSF, whereas 10 were mobilized twice. Twenty-three patients (62%) were successfully (MNC >3.5 x 10(8)/kg, CFU-GM >1.0 x 10(4)/kg, CD34+ cells >2.0 x 10(6)/kg and no Ph+ cells in the apheresis product) [n = 16] or partially successfully (as defined above but 1-34% Ph+ cells in the apheresis product) [n = 7] mobilized. There was no mortality during the mobilization procedure. Twenty-one/23 patients subsequently underwent auto-SCT. The time with PMN <0.5 x 10(9)/l was 10 (range 7-49) and with platelets <20 x 10(9)/l was also 10 (2-173) days. There was no transplant related mortality. The estimated 5-year overall survival after auto-SCT was 68% (95% CI 47 - 90%), with a median follow-up time of 5.2 years.We conclude that in a significant proportion of patients with CML in CP 1, intensive chemotherapy combined with G-CSF mobilizes Ph- BSC sufficient for use in auto-SCT.
|
| pubmed:commentsCorrections | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte Colony-Stimulating...,
http://linkedlifedata.com/resource/pubmed/chemical/Hydroxyurea,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-gamma,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/lenograstim
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Sep
|
| pubmed:issn |
1042-8194
|
| pubmed:author |
pubmed-author:BjörkholmMagnusM,
pubmed-author:BraideIngerI,
pubmed-author:CarlsonKarinK,
pubmed-author:GahrtonGöstaG,
pubmed-author:GrimforsGunnarG,
pubmed-author:HöglundMartinM,
pubmed-author:HastRobertR,
pubmed-author:LöfvenbergEvaE,
pubmed-author:LernerRickardR,
pubmed-author:LinderOlleO,
pubmed-author:LjungmanPerP,
pubmed-author:MalmClaesC,
pubmed-author:NilssonPer-GunnarPG,
pubmed-author:ObergGunnarG,
pubmed-author:Olsson-StrömbergUllaU,
pubmed-author:PaulChristerC,
pubmed-author:RödjerStigS,
pubmed-author:SimonssonBengtB,
pubmed-author:StenkeLeifL,
pubmed-author:TidefeldtUlfU,
pubmed-author:TuressonIngemarI,
pubmed-author:UdenAnn-MarieAM,
pubmed-author:VilenLarsL,
pubmed-author:WahlinAndersA,
pubmed-author:WinqvistIngemarI,
pubmed-author:ZettervallOlleO
|
| pubmed:issnType |
Print
|
| pubmed:volume |
47
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1768-73
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:17064986-Adjuvants, Immunologic,
pubmed-meshheading:17064986-Adolescent,
pubmed-meshheading:17064986-Adult,
pubmed-meshheading:17064986-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17064986-Combined Modality Therapy,
pubmed-meshheading:17064986-Feasibility Studies,
pubmed-meshheading:17064986-Female,
pubmed-meshheading:17064986-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:17064986-Hematopoietic Stem Cell Mobilization,
pubmed-meshheading:17064986-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:17064986-Humans,
pubmed-meshheading:17064986-Hydroxyurea,
pubmed-meshheading:17064986-Interferon-gamma,
pubmed-meshheading:17064986-Leukapheresis,
pubmed-meshheading:17064986-Leukemia, Myelogenous, Chronic, BCR-ABL Positive,
pubmed-meshheading:17064986-Male,
pubmed-meshheading:17064986-Middle Aged,
pubmed-meshheading:17064986-Recombinant Proteins,
pubmed-meshheading:17064986-Salvage Therapy,
pubmed-meshheading:17064986-Transplantation, Autologous
|
| pubmed:year |
2006
|
| pubmed:articleTitle |
Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase.
|
| pubmed:affiliation |
Department of Internal Medicine, University Hospital, SE-751 85 Uppsala, Sweden. ulla.olsson.stromberg@akademiska.se
|
| pubmed:publicationType |
Journal Article
|